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The task of reviewing this subject in any depth is overwhelming.
A literal barrage of information has been published over the past
50 years on immune-inflammatory-mediated physiologic and
pathologic processes in skin. This information has resulted in leaps
of knowledge, examples of which include the following.
(1) Moving from a simplistic knowledge of classes of immuno-
globulins to the molecular structure of antibody; the gene
interacttion needed to generate antigen specific antibodies;
and the regulation of antibody production.
(2) Moving from the discovery that cellular and humoral immune
responses were antigen-specific but housed in the mystical
black box inherent to in vivo assessments to an appreciation of
the complexity of antigen presentation and sensitization via
interaction of specific cells, molecularly defined antigen
specific receptors, molecules of the major histocompatibility
locus, cytokines, and an appreciation that this complex
receptor ligand interaction is dynamic and regulated by the
gene product repertoire inherent to specific cell types.
(3) Moving from the clinical recognition that signs of inflamma-
tion accompany immunologic events in the skin to realizing
that several inflammatory cascade systems are operative and
interactive, important examples of which include the comple-
ment activation pathway and its variants, release of cytokines
(the interleukins and others) by cells of not only the immune
system, the protease/antiprotease systems, arachidonic acid
cascade pathways, and the generation of unstable oxygen
radicals.
(4) Moving from the clinical observation that many endogenously
driven inflammatory skin diseases were not expressed in other
organs to gaining an appreciation of the likelihood that skin
may have cellular components of the immune system that
selectively travel to skin, skin-associated lymphoid tissue
(SALT).
Two highly interactive components have driven this barrage
investigators and technology.
In the usual scenario of this interaction, investigators generate
the questions that result in advances in technology. Application
generates answers which lead investigators to synthesize new
concepts, generate hypotheses, and set the circuit in motion once
again to generate new questions and new technologies. The Society
for Investigative Dermatology and now the European Society for
Dermatologic Research, through their journal, The Journal Investi-
gative Dermatology (JID), have been pivotal to advances in the
understanding of skin and its disorders. This has been accomplished
by providing a forum for exchange of information of technologies
and findings among investigators and clinicians who are dedicated
to the study of the biology and pathology of skin. A significant
portion of this exchange of information has been in the area of
inflammation and immunology of the skin and its disorders.
We have chosen to review ‘‘Immunology/Inflammation of the
Skin and its Related Disorders’’ on this 50th anniversary of the JID
from the perspective of how technology has furthered our under-
standing of the basic immunologic/inflammatory processes of skin.
This has been done by utilizing progress in our understanding of
contact allergic dermatitis and bullous diseases which develop at
the basement membrane zone (BMZ). By being selective, we have
narrowed our charge significantly but have still surely overlooked
many important contributions.
TECHNOLOGICAL ADVANCES IN BASIC IMMUNOLOGY
OF SKIN AND IN CONTACT ALLERGIC DERMATITIS
The reason why we have chosen allergic contact hypersensitivity
(ACH) as an example for demonstrating the progress we have made
during the past 50 years in understanding immune reactions
involving the skin is severalfold. First, ACH is a frequent and
serious medical problem. Second, at least partial elucidation of the
complex series of events occurring in both the induction and
elucidation phase of ACH would have been impossible without the
application of the powerful tools modern biotechnology has
provided. Third, we will show that in the search for the pathogenetic
principles operative in ACH, the important discovery was made that
the skin, particularly the epidermis, is a unique immunologic
microcosmos that contain many of the cellular constituents needed
for the initiation, modulation, and elicitation of the immune
response.
1938–1970: Allergic Contact Hypersensitivity—A Special Form of
Delayed-Type Hypersensitivity In the search for the etiology of
eczema, it was frequently noted that contact with simple chemicals
resulted in the development of eczematous lesions. Between
1935–1950, many important facts about contact hypersensitivity
were disclosed by means of simple chemicals. In 1935 and 1936,
Landsteiner and Jacobs [1,2] investigated the sensitizing capacity of
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nitro-substituted and chloro-substituted benzenes in guinea pigs and
showed that these chemicals sensitize only when the particular
compound possesses a labile substituent that allows its conjugation
with structural proteins of the host. Benacerraf and Gell [3] would later
demonstrate that the specificity of the ensuing delayed-type hypersen-
sitivity reaction is determined by the entire hapten-carrier complex.
In 1938, Marion Sulzberger and Rudolf L. Baer, published an
article in Volume 1 of the Journal of Investigative Dermatology
dealing with the relationship between chemical structure and
in vitro properties and the capacities of five different nitrobenzenes
to produce eczematous sensitization in man [4]. They found that
when injected intracutaneously into guinea pigs the capacity of
these substances to produce contact dermatitis closely paralleled
their skin-sensitizing ability and appeared to be related to the
lability of their Cl or NO2 groups and to their capacity to produce
conjugates with autologous larger molecules. This study [4] was the
first demonstration in man of a relationship between the in vitro
reactivity of a chemical and its capicity to produce eczematous
contact allergic sensitization.
In these and several other studies published during the late
1930s and 1940s, the immunologic nature of the ACH reaction was
clearly documented: After a sensitization period of variable length,
the ACH reaction can be elicited by epicutaneous application of the
antigen. As opposed to various antibody-mediated hypersensitivity
(e.g., immediate hypersensitivity, Arthus reaction), ACH is delayed
in onset and reaches its peak intensity 48–72 h after initiation. The
time kinetics of this response are similar to that of the delayed-type
hypersensitivity (DTH) phenomenon initially observed by Koch at
the turn of the century in the dermal reactivity of tuberculous men
and animals towards tuberculin, a mycobacterial product. The
similarity between ACH and DTH was further underscored by the
finding that in experimental animals both ACH [5] and DTH to
tuberculin [6] could be transferred to naive recipients by live
lymphoid cells, but not by serum from the immune donors.
Similar transfer experiments were performed with highly
sensitive human donors, and while there is no question about the
transferability of tuberculin-type DTH [7], the results in ACH were
quite contradictory: some investigators succeeded [8], others failed
9.10]. Although the actual reason for this discrepancy has not been
resolved, its mere existence pointed towards an interesting problem
immunology, i.e., the relationship between ACH and tuberculin-
type DTH. Although most immunologists considered these reactions
practically alike, it was difficult to explain why ACH could not be
engendered in certain species of laboratory animals in which
tuberculin-type DTH could be readily induced (e.g., in rabbits).
Therefore, the concept emerged that certain differences between
tuberculin-type DTH and ACH could be due to differences in the
cellular and molecular composition of the tissues used for induction
and/or elicitation of the immunologic reaction.
It was already well known that the mode of antigen adminis-
tration greatly influences the outcome of the immunologic reaction
in the mid 1940s. In 1946, Merrill Chase showed that feeding a
sensitizing chemical to a naive animal would abort or significantly
reduce the development of DTH when an attempt was later made to
sensitize with the same compound [11]. In other experiments with
guinea pigs, it was demonstrated that a long-lasting state of antigen-
specific unresponsiveness was obtained by intravenous application
of water-soluble forms of a given contact sensitizer prior to or
shortly after sensitization [12,13]. In a similar fashion, Harber et al
14] observed a significant reduction in the susceptibility to
sensitization to DNCB in the offspring of guinea pigs that were
intraperitoneally injected with DNCB during pregnancy. Also, this
actively acquired tolerance was antigen-specific, because it did not
extend to mmunologically unrelated compounds. These observa-
tions, i.e., that simple chemicals would induce strong sensitization
when introduced via the skin, but would induce specific unrespon-
siveness then administered via other routes, was in keeping with
and supported the concept that the specificity of the DTH reaction is
determined by both the hapten and the protein carrier [3,15,16].
Experimental support for this was provided by Gell and Benacerraf
[17] who found that guinea pigs sensitized by injection of
unconjugated picryl chloride plus adjuvants tend to react more to
contact with picryl chloride than to intradermally injected picryl-
protein conjugate, while guinea pigs sensitized with a picryl-protein
conjugate plus adjuvants give poorer contact than intradermal
reactions.
If the carrier protein was indeed of such importance for the
specificity of the ACH reaction, one had to assume that the route of
antigen administration during the sensitization and elicitation
process would be of decisive importance, because this route
determines the proteins available as carriers. These considerations,
i.e., the postulated role of epidermal (e.g., keratin) and/or dermal
(e.g., collagen) proteins in the induction and elicitation of ACH, led
to the concept [18] that, from an immunologic viewpoint, the skin is
distinct from other tissues and, due to its specific structural
elements, is endowed with potent sensitizing capacities in the
induction of ACH.
Strong support for the sensitizing potential of the antigenic
complex formed in the skin came from the classical experiments by
Macher and Chase [19,20]. These authors studied the onset of
sensitivity to picryl chloride and DNCB by utilizing one ear of
guinea pigs for intradermal injection and excising the ear at various
times. Contact testing was done 2 weeks later and readings were
made at 24 and 48 h. Despite escape of allergen from the injected
ear in the first few hours after injection, it was the small amount of
chemical that remained in the ear which appeared to be the
sensitizing depot, and excisions of the depot were highly effective in
interfering with the process of sensitization (Fig 1). Even more
Figure 1. Figure 2 from the classic paper by Macher and Chase (J. Exp. Med.
129:103–121, 1969), which demonstrated that excision of the small depot of
contact sensitizer applied to a guinea pig ear interfered with eventual
sensitization. (Reprinted with permission.)
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interesting was the finding that animals from which the ear was
excised rather early were impaired in their capability to be made
sensitive to the same chemical at a later time, indicating a
tolerogenic effect of the escaping allergen (Fig 2).
It was assumed that the highly reactive chemical forms
complexes with epidermal/dermal proteins and that these putative
hapten/skin protein complexes comprise the peripheral sensitizing
reservoir.
1970–1988: Allergic Contact Hypersensitivity—Role of Epidermal
Cells in the Process of Sensitization Further progress in the
understanding of the mechanisms of sensitization was hampered
by the lack of techniques to reliably assess lymphocyte activation
in vitro. This situation changed dramatically when it was found that
uptake of tritiated thymidine by nucleic acids of lymphocytes in
culture correlates well with transformation into blast cells [21].
Using this method, several studies have shown that lymphocytes
from contact-sensitized human or guinea pig donors could be
activated in vitro by haptens conjugated to epidermal extracts,
erythrocytes, or leukocyte antigens [22–25], all of which were
considered to be the normal carriers for in vivo hapten sensitization.
However, Geczy and Baumgarten [26] found that lymphocytes
from DNCB-sensitized guinea pigs could be activated in vitro only
by direct DNFB-treatment of viable leukocytes, but not by DNFB-
treated killed leukocytes, erythrocytes, or serum proteins. This
observation suggested that the relevant carrier in hapten-specific
T-cell responses is a viable leukocyte rather than a carrier protein
per se and opened the possibility that, in states of contact sensitivity,
T cells may be primarily sensitized to simple chemical haptens
associated with a specialized stimulator cell. This concept also
seemed reasonable in view of certain discoveries made in the early
1970s, which revolutionized our way of thinking with regard to the
induction of antigen-specific T-cell responses: a) Recognition of
soluble protein antigens by T lymphocytes requires an initial uptake
and ‘‘processing’’ of these antigens by macrophages; and b) the
functional interaction between antigen-bearing macrophages and
T lymphocytes is mediated via gene products encoded for by the
I-region of the major histocompatibility complex (MHC) of the
species, the immune response-associated (Ia) antigens [27].
Soon it was found that these rules were not only valid for the
induction of T-cell responses to soluble protein antigens, but also for
hapten-specific T-cell activation. Thomas et al [28] showed that
T cells from picryl chloride-immune guinea pigs could only be
restimulated by TNP-conjugated macrophages, but not by
TNP-conjugated erythrocytes, thymocytes, or nonadherent lymph
node cells. More importantly, these authors demonstrated that
TNP-modified Ia-bearing macrophages were capable of inducing
hapten-specific sensitization in non-immune T cells in a MHC
I-region-restricted fashion [29]. These results implied that an
la-bearing macrophage-like stimulator cell is required for the
induction of contact sensitivity and, in view of the results of Macher
and Chase [19,20], suggested that this stimulator cell may be
localized in the skin.
At approximately the same time, Inga Silberberg, Jeanette
Thorbecke, and Rudolf Baer carried out a series of ultrastructural
studies concerning the morphologic features of contact allergic
reactions and made a number of very important findings, which
suggested that Langerhans cells (LC) are of great importance for
induction and elicitation of ACH. These investigators observed a
close apposition of mononuclear cells (probably lymphocytes) to LC
(Fig 3), defined by the presence of Birbeck granules [30] (Fig 4), and
damage to some LC at sites of specific challenge to a variety of
contact allergens, but not at sites of primary irritant dermatitis. Such
apposition was seen in actively sensitized patients and guinea pigs
as well as in passively sensitized guinea pigs. In passively sensitized
guinea pigs, LC were found in dermal lymphatics and were greatly
increased in number in the dermis after challenge with the contact
allergen [31]. In subsequent studies, Silberberg and co-workers
provided some evidence which suggested that LC can pick up
antigens in the skin and carry them by way of dermal lymphatics to
draining lymph nodes [32].
These studies were the starting point for an exciting and rapidly
expanding new field of research which has attracted the attention of
an ever increasing number of investigators during the past 10 years
the exploration of immune functions of epidermal cells.
It is far beyond the scope of this paper to give a detailed account
of the excitement of these years, and the following discussion of
major accomplishments made is highly selective and subjective and
cannot give appropriate credit to many important contributions
made in this area.
In 1977, LC were shown to be the only cells within the normal
epidermis to express Fc-IgG and C3 receptors as well as Ia antigens
[33,34,35] (Fig 5). Soon thereafter, the bone marrow origin of these
cells was established by using allogeneic bone marrow-chimeric
mice [36,37] (Table I). Functional studies performed in several
species revealed that epidermal cells are potent stimulators of
antigen (soluble proteins, haptens, alloantigens)-specific prolifera-
tive and cytotoxic responses in sensitized and resting T cells, and
that this functional capacity of epidermal cells was critically
dependent upon the presence of viable Ia-bearing LC
[38,39,40–42] (Fig 6). An-other important functional property of
LC was disclosed by the finding that LC containing no foreign
antigens (alloantigens, haptens) on their surface can trigger the
generation of cytotoxic T cells against antigenic moieties on cells
Figure 2. Figure 3 from the Macher and Chase classic, which showed that
animals were resistant to subsequent sensitization if the ear containing the
sensitizer was removed rather early—implying a tolerogenic stimulus.
(Reprinted with permission.)
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that by themselves are not able to induce activation of resting T cells
[43]. This may indicate that LC play a key role in the generation of a
protective effector T-cell response towards a variety of antigens
(alloantigens, haptens, microbial antigens, differentiation and tumor
antigens) expressed on their epidermal symbionts, i.e., keratinocytes
and melanocytes. Collectively, all these in vitro data strongly
suggest that the major in vivo function of LC is to provide the
principal sensitizing signal in skin-induced immune responses.
In the case of ACH, a series of elegant experiments have proven
this to be the case. (While in the early days the guinea pig was the
model of choice for the study of ACH, most in vivo studies of ACH
are now performed in the mouse [44]. This is probably due to the
fact that, from an immunologic viewpoint, the mouse is the best-
studied animal species.) Based on the observations that 1) the tail
skin of mice is naturally deficient in LC when compared to the
density of these cells in normal body wall skin [45], and that 2) LC
in ultraviolet radiation-treated skin areas are phenotypically altered
[46,47], Toews et al [48] painted mice with DNFB on either normal
body wall skin or on skin naturally deficient in (tail) or artificially
(UV-B) depleted of functioning LC. They found that LC-deficient
skin fails to sustain induction of contact hypersensitivity [48] (Fig 7).
This is not simply a null event, because a state of specific immu-
nologic unresponsiveness ensues [48] (Fig 8), which is associated
with and probably caused by the generation of suppressor
T lymphocytes [49].
The sensitizing potential of LC is also shown by experiments
where hapten-modified, LC-enriched epidermal cells induce
sensitization even when immunizing conditions are chosen that
usually result in antigen-specific immune tolerance [50]: while
hapten-modified macrophages can sensitize an experimental
animal when applied subcutaneously, they fail to do so when
administered intravenously, in which case they induce specific
unresponsiveness. In contrast, hapten-modified epidermal cells
enriched for LC not only induce sensitization via the intravenous
route [50,51] but also overcome the tolerizing potential of hapten-
modified, concommitantly administered macrophages [50]. Finally,
it has now been clearly established by Hauser et al [52] that hapten-
modified LC, but not other hapten-modified Ia-bearing leukocytes,
deliver signals to naive T cells in vitro which result in the
propagation of hapten-specific T cells and the generation of
hapten-specific T-cell lines. This hapten-specific T-cell pool
generated by in vitro sensitization with hapten-bearing LC is
Figure 3. Contact allergic reaction at 3 h in an actively sensitized guinea pig.
A mononuclear cell (M) is seen in apposition to a Langerhans cell (L) in the
epidermis. A Langerhans cell granule is seen at the arrow and at higher
magnification in the inset. The surrounding keratinocytes (K) show a sparsity
of desmosomes in areas adjacent to the mononuclear cell and Langerhans cell
(stained with uranyl acetate and lead citrate,  12.500; inset  96,000)
(Silberberg et al: J Invest Dermatol 66:210–217, 1976).
Figure 4. A classic photograph from the highly cited paper by Birbeck
Breathnach, and Everall describing the distinctive organelle now known as
Birbeck granule (J Invest Dermatol 37:51–64, 1961). The photograph is an
electromicrograph of the cytoplasm of a ‘‘high-level clear cell’’ (Langerhans
cell) 140,000. Sections of the characteristic granule are shown in various
places. ‘‘Bulging’’ of the outer membranes is seen in two granules, producing
a tennis-racket-like appearance. The inset shows a section of a ‘‘premelanin
granule’’ (p) from the Golgi region of a human hair bulb. The authors
observed that the striation of the two types of granule were similar, and
inferred from this that the Langerhans cell and melanocyte were related,
Although this concept was erroneous, the usefulness of the Birbeck granule to
identify Langerhans cell has endured.
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capable of directly mediating the effector phase of contact
hypersensitivity (Hauser, personal communication).
In 1981, Sauder et al [53] reported that subcutaneous
immunization with hapten-derivatized epidermal cells induced
ACH, whereas inoculation with UV-irradiated, hapten-derivatized
epidermal cells resulted in antigen-specific unresponsiveness. These
observations were interpreted to mean that UV radiation inactivates
the antigen-presenting capacity of LC, but they also indicated that a
cellular source of a down-regulating signal must exist within the
epidermis.
We must now digress for a moment from the discussion of ACH
and expand on the issue of the epidermis containing cellular
elements other than LC capable of modulating the immune
response. It is now well established that keratinocytes are a rich
source of a variety of mediators of both the inflammatory and the
immune response. They include arachidonic acid metabolites
[54–56], which will be discussed by Camp, and a group of
Figure 5. This immunofluorescence photograph of mouse skin shows
dramatic staining of suprabasal dendritic cells with anti-Ia antisera, plus
staining of dendritic cells in the dermis (Rowden: J Invest Dermatol 75:22–31,
1980).
Table I. Detection of Major Histocompatibility Alloantigens on Epidermal Cells of Chimeric Mice Soon after
Chimerizationa
Donor Recipient Daysb
% Ia-Positive
(from donor)
% Langerhans Cells
(from donor) Controls % Ia-Positive
BALB/c C57BL/6 7 0 0 BALB/c 4.2
13 0.4 — C57BL/6 3.9
18 0.5 9
32 1.2 34
aC57BL/6 mice were irradiated with 850 R and within 2 h were given 2.5 to 3 107 BALB/c bone marrow cells.
bAfter chimerization.
(Table from Tamaki and Katz: J Invest Dermatol 75:12–13, 1980.)
Figure 6. Dependence on intact Ia positive Langerhans cells for T-cell
stimulation (Aberer et al: J Invest Dermatol 79:129–135, 1982).
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polypeptide mediators, which are collectively called cytokines and
function in vitro and in vivo at subnanogram levels. Most of these
soluble mediators have been characterized not only on the basis of
their biologic activity, but also at the biochemical and genetic level.
The first keratinocyte-derived cytokine described was termed
ETAF (epidermal cell-derived thymocyte activating factor) [57,58]; it
was found to be biologically and biochemically essentially
indistinguishable from interleukin-1 (IL-1) [59], and molecular
biologic studies have confirmed this [60,61] (Fig 9). It is remarkable
that while mononuclear phagocytes do not produce IL-1 constitu-
tively, the normal epidermis contains large amounts of functionally
active IL-1 [62,63]. In view of the diverse biologic activities of IL-1
(e.g., co-stimulation with mitogens of thymocyte/T-cell proliferation
and interleukin-2 (IL-2) production, stimulation of B-cell function,
keratinocyte proliferation, fibroblast proliferation, prostaglandin E2
and collagenase production by fibroblasts, muscle proteolysis, and
fever induction), it appears that epidermal IL-1 production/secretion
and its alteration by certain physicochemical agents [64,65] plays
Figure 9. IL-1 is a major functional component of ETAF (Bell et al: J Invest
Dermatol 88:375–379, 1987).
Figure 7. Failure of Langerhans cell-deficient skin to sustain induction of
contact hypersensitivity (Streilein et al: J Invest Dermatol 74:319–32 1980).
Figure 8. Specific unresponsiveness follows attempts to induce contact
hypersensitivity in Langerhans cell depleted skin [48].
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an important role in the regulation of immune cell and inflammatory
cell function under both physiologic and pathologic conditions.
In addition to IL-1, epidermal cells produce protein factors that
govern growth, differentiation, and function of certain hematopoie-
tic as well as non-hematopoietic cells, i.e., molecules with
interleukin-3-like activity [66,67], granulocyte/monocyte-colony
stimulating factor (GM-CSF) [68], and interleukin 6 (IL-6) [68a–c].
Again, the careful investigation of expression patterns of the genes
encoding these cytokines in keratinocytes will be important for
understanding their biologic role in immune/inflammatory reactions
involving the skin. In addition, several other biologic activities have
been described in culture supernatants of both freshly isolated and
transformed keratinocytes, e.g., ELDIF (epidermal cell-derived
lymphocyte differentiation factor) [69]. It is not yet clear whether
each of these activities corresponds to a molecularly distinctive
cytokine or is rather due to a pluri (oligo) potency of one given
factor. Of potential importance for the mechanism(s) by which
UV-irradiation of skin or epidermal cells alters their capacity
to induce ACH (see above) is the finding that UV irradiation of
mice/epidermal cells results in the production/release of mediators
which can interfere with the induction of ACH [70,71] and can
inhibit IL-1 [72].
Before we return to the discussion of ACD, we must address a
fundamental question relating to the postulated role of the skin/
epidermis in the immune response: What about the lymphocytes? In
other words, do the antigen-presenting cells and immunomodula-
ting cytokines of the epidermis have a target in the skin to act upon?
A key observation in this context was the finding that certain
T-lymphocyte malignancies show a distinct propensity for infiltra-
tion of the skin. The term cutaneous T-cell lymphomas (CTCL) has
been used to identify this phenomenon [73]. Among these
malignant T cells, it is the helper/inducer rather than the
cytotoxic/suppressor subset which exhibits this propensity to
infiltrate the skin, including the epidermis [74]. The question is
whether this epidermotropism of neoplastic helper/inducer
T lymphocytes is a unique feature of the neoplastic cell or,
alternatively, an amplification of a normally ongoing process.
Immunophenotypic studies on the localization of lymphocyte
subpopulations within normal human skin showed that lympho-
cytes within the skin are of T- rather than B-cell nature, and indicate
that most of the T cells are found in the dermis, and not in the
epidermis [75,76]. Intradermal lymphocytes are preferentially
clustered around postcapillary venules and around the appendages
and consist of both CD4þ and CD8þ cells [76]. Intraepidermal
lymphocytes reportedly account for less than 10% of all skin T cells
and appear to express predominantly the CD2þ / CD3þ /CD8þ
phenotype [75–77] (Fig 10).
As opposed to these still poorly defined T cells within the human
epidermis, lymphoid elements within the mouse epidermis have
been extensively characterized. In 1983, two groups of investigators
reported independently on the intraepidermal existence of Ia
dendritic cells that expressed large amounts of surface-bound Thy-1
antigens [78,79] (Figs 11 and 12). These cells were therefore termed
Thy-1þ dendritic epidermal cells (Thy-1þDEC) and were soon
found to be of bone marrow origin [80–82]. The availability of
antibodies against various T-cell differentiation antigens as well as
the possibility to propagate Thy-1þDEC by means of mitogens and
IL-2 [83,84] made it possible to clarify the lineage of these cells.
Although Thy-1þDEC and cell lines derived from them lack CD5,
CD4, and CD8 antigens, they are potentially functioning T cells as
evidenced by the expression of CD3-associated T-cell receptors
(TCR) on their surface [85–87], On most peripheral T cells, the CD3
complex is associated with the disulfide-linked TCR a/b heterodimer
that is responsible for MHC-restricted antigen recognition [88]. In
contrast, CD3 antigens on most Thy-1þDEC and Thy-lþDEC-
derived cell lines are linked to another disulfide-linked heterodimer
representing the product of rearranged TCR g and d genes
[86,87,89]. A similar type of TCR has been described on human
and murine thymocytes [90,91] and on a small subset of peripheral
T cells [92–94]. Although the function of this CD3-associated g/d
TCR is not yet clear, some evidence exists that it is involved in non-
MHC restricted antigen recognition [95,96]. The reported capability
of certain g/d TCR-bearing cells to kill target cells in a non-MHC-
restricted fashion [95,96] places them in a rather broadly defined
category of lymphocytes with generalized cytotoxic activity that
does not require prior sensitization and that is directed against a
broad range of targets. The appearance of g/d TCR early in ontogeny
[97] may suggest that it is a phylogenetic precursor of the a/b
heterodimer and perhaps provides protective immunity to the fetus
against common pathogens before the development of MHC-
restricted CD3-associated a/b TCR structures. But, even in the adult,
it is conceivable that g/d TCR-bearing cells in the periphery express
antigen recognition structures not provided by the a/b TCR
repertoire. The fact that the functional role of CD3-associated g/d
TCR complexes is still obscure makes speculations about the
possible function of Thy-1þDEC difficult and cumbersome. This
Figure 10. The Skin Immune System (SIS) as depicted by Bos et al: J Invest
Dermatol 88:569–573, 1987.
38S GERALD G. KRUEGER AND GEORG STINGL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
issue is further clouded by the fact that an equivalent to murine
Thy-1þDEC has not yet been identified in man [75,98]. It
remains to be seen whether some of the T cells within the human
epidermis [76,77] express TCR analogous to those expressed on
Thy-1þDEC.
A possible clue about the in vivo function of Thy-1þDEC stems
from observations by Sullivan et al (51) which bring us back to our
main subject of discussion, i.e. the mechanisms operative in the
induction of ACH. These investigators found that, while i.v.
administration of hapten-modified LC induces a contact hyper-
sensitivity response without down regulation, hapten-modified.
Thy-1þDEC fail to do so. Their lack of sensitizing power, however,
is not an immunologic null event: attempts to resensitize an animal
which previously received hapten-modified Thy-1þDEC result in
the down regulation of the subsequent contact hypersensitivity
response. These data are in keeping with results by Bigby et al [99],
who showed that the intensity of an ACH response in a given mouse
strain correlates well with the ratio of IaþLC to Thy-1þDEC.
Collectively, these findings support the concept that application of
an antigen in the context of Thy-1þDEC results in the generation of
antigen-specific suppressor cell circuits. This, however, does
exclude the possibility that other epidermal cells exist which can
also function as antigen-presenting cells in the activation of
supression [100].
If we then assume that the outcome of an immune response to
contact sensitizing agents is influenced by the existing balance
between the dendritic, bone marrow-derived epidermal cell
populations, the question about the site of interaction between
antigen-presenting cells and lymphocytes needs to be further
discussed. Does it occur in the skin or in the draining lymph node?
Several types of experiments have indicated the need for patent
lymphatics for the onset of sensitization [101,102]. Macher and
Chase [19,20], however, found that a direct lymphatic pathway was
not needed, because surgical removal of the draining auricular node
failed to inhibit sensitization irrespective of removal made before-
hand, or 15min, 3 h, or 6 h after injection of hapten into the ear.
They proposed that the early phase of induction, termed peripheral
sensitization [103], actually took place within the haptenated skin
and that the role of the lymph node was to amplify the response
already initiated within the skin. Even in 1988, the answer to the
above question is not yet known. The finding of antigen-bearing LC
in the dermal lymphatics and draining nodes during the sensitiza-
tion period [32,104] may indicate that LC, after having picked up
the antigen in the epidermis, carry it by way of dermal lymphatics to
the draining lymph nodes, but one cannot exclude the possibility
that they also functionally interact with T cells in the skin.
Figure 12. Ultrastructural verification that the Thy-1.2þ dendritic epidermal
cell was not a Langerhans cell (Bergstresser et al: J Invest Dermatol
11:286–288, 1983).
Figure 11. Identification of murine Thy 1þ epidermal cells by
immunofluorescence. A and B: Sheets of C3H/He ear epidermis were fixed
with 2%; paraformaldehyde (0.1 Cacodylate buffer, 0.017M CaCl2) for
20min at room temperature. After three PBS washes sheets were exposed to a
1:100 dilution of a FITC-labeled rat IgG2b anti-mouse Thy-1.2 monoclonal
antibody for 16 h at 41C (A). In a few reactions, sections were exposed to the
dopa reaction for the demonstration of tyrosinase activity before being
exposed to the immunofluorescence procedure. Dendritic Thy-1.2 positive
cells are seen between keratinocytes in A, and are clearly different than
dendritic Dopa-positive melanocytes in B. Additional experiments with
epidermal cell suspensions confirmed that the Thy-1þ cells were not Ia-
positive Langerhans cells (Tschachler et al: J Invest Dermatol 81:282–285,
1983).
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Recently, Schuler et al [105,106] demonstrated that differences
exist in the sensitizing potential between freshly isolated LC and LC
cultured for 72 h in the presence of keratinocytes: While freshly
isolated LC were potent stimulators of sensitized T cells but not of
testing T cells, cultured LC exhibited both functions. This functional
maturation process of LC, which requires the presence of GM-CSF
and IL-1 [107,108], is also reflected in phenotypic changes in that,
upon culture, LC lose their Fc-IgG receptors, ATPase activity, and
Birbeck granules, but increase their surface Ia density and come to
resemble the so-called Ia-bearing dendritic cells of the lymphoid
organs known to be potent stimulators of resting T cells. It is thus
conceivable, but unproven, that in the induction phase of ACH, LC
pick up the antigen in the skin, migrate via the dermal lymphatics to
the lymph node, thereby changing their phenotype and function,
and then elicit as ‘‘dendritic cells’’ the activation of T cells finally
mediating ACH. In analogy to classical DTH [109,110] it is likely
that the effector cells of ACH, which by an as yet undefined
mechanism injure the antigen-bearing epidermal cell targets,
belong to the CD4þ , CD8, T-cell subset [111]. Interestingly,
antigen-specific as well as antigen-nonspecific T-cell blasts gener-
ated in lymph nodes draining the skin preferentially infiltrate
cutaneous sites of hapten-induced inflammation, while blast cells
obtained from rat mesenteric lymph nodes accumulate after
adoptive transfer in highest number in the gut wall and the
mesenteric lymph nodes [112,113]. The reason for these prefer-
ential homing patterns is not yet clear, but may be dependent on the
expression of specific homing receptors expressed on endothelial
venules [114], Upon entry into the tissue, activated T cells can
produce a variety of effector and modulatory cytokines, e.g.,
interferon-g, which can bind, via high affinity receptor sites, to
cultured human keratinocytes [115], and induce MHC class II
antigens on these cells [116,117] (Table II). Immunohistochemical
analysis of skin biopsies from sites of ACH reactions reveals the
presence of class II antigens (HLA-DR4HLA-DQ, HLA-DP) on
keratinocyte surfaces [118,119]. At least in vitro, these Ia-bearing
keratinocytes, although incapable of eliciting primary antigen-
specific T-cell responses, can activate sensitized T cells [120,121]
and may therefore represent important stimulators of and/or targets
for ACH effector cells. However, the more recent finding that
incubation of TNP-specific T-cell clones with TNP-modified Iaþ
keratinocytes results in their unresponsiveness to subsequent
stimulation with TNP-modified LC [121a] rather suggests that class
II MHC-bearing keratinocytes provide signals down-regulating and,
finally, terminating ACH reactions.
This brief tour d’horizon over the major developments in the
field of ACH made during the past 50 years hopefully shows that the
initiation, regulation, and final outcome of this particular type of
immune response is dictated by cellular elements found within skin
itself. It was therefore quite appropriate and justified to emphasize
the constituting elements of cutaneous immune responses. In 1978,
Streilein [122] coined the term SALT (Skin-Associated Lymphoid
Tissues) to propose the existence of an integrated system of immune
surveillance designed uniquely for the skin. SALT is comprised of a)
potent antigen-presenting cells (Langerhans cells); b) distinctive
populations of T lymphocytes, some of which preferentially
infiltrate the epidermis; c) keratinocytes that produce several
immunomodulatory cytokines; and d) a set of draining peripheral
lymph nodes, integrating this multicellular system, which contain,
along with the dermis, blood vessels with endothelial cells whose
surfaces capture lymphocytes passing through the blood [123].
It does not take much imagination to predict that while the past
10 years were primarily dedicated to the exploration and dissection
of the circuits and signals of SALT, in the not too distant future we
will develop experimental and, finally, therapeutic strategies to
selectively regulate and influence these circuits.
It must again be mentioned that the progress made has only been
possible through the development of powerful new technologies
and by their application to the epidermal substrate. These
techniques include sophisticated immunolabeling techniques of
tissue specimens and single cells, cell separation techniques, culture
of epidermal cell and lymphoid subpopulations, assays for various
lymphocyte functions, assays for determining the functional
activities of soluble mediators of immune responses and inflamma-
tion, hybridoma technology, analytical protein chemistry, assess-
ment of gene expression, cell cloning, cell transformation, gene
cloning, etc. This resulted in the intensive collaboration between
scientists from inside and outside dermatology. The fact that non-
dermatologic scientists are now frequently choosing the skin to
study the cellular and molecular mechanisms of immune responses
is a great challenge for investigative dermatologists and great care
has to be taken to secure the active contribution of dermatologists in
this field.
Table II. Effect of Recombinant Gamma Interferon on
Cultured Human Keratinocyte HLA-DR Expression
A. Keratinocyte Culturesa
HLA-DR Staining
Experiment Meanb % Stainedc
Experiment 1
Control 0.5 0
Gamma interferon treatedd 130.0 72.0
Experiment 2
Control 0 0
Gamma interferon treated 68.0 64.0
Experiment 3
Control 0 0
Gamma interferon treated 84.0 54.0
B. LC-depleted Keratinocyte Culturesa
HLA-DR and OKT-6 Staining
Experiment Meanb % Stainedc
HLA-DR
Control 1.0 1.0
Gamma interferon treated 89.0 50.0
OKT6
Control 0 0
Gamma interferon treated 5.0 0
aNonspecific and Fc receptor-mediated background staining has been
subtracted.
b,cMean expression of fluorescence per cell and percent of cells with
detectable staining were analyzed by FACS on setting: fluorescence=2,
scatter=1, photomultiplier tube 650.
d100 units/ml.
(Table from Basham et al: J Invest Dermatol.)
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TECHNOLOGICAL ADVANCES IN BULLOUS DISEASES IN
SKIN WITH IMMUNOREACTANTS AT THE BMZ
Historical Perspective To set the stage for this overview of
technologically driven advancements in bullous diseases, where
immunoreactants at the BMZ are likely etiopathogenic, a synopsis
of the recent history of these diseases is presented. The year of the
founding of the Society for Investigative Dermatology (1938) was
also the year that Andrews published the second edition of his
textbook Diseases of the Skin for Practitioners and Students. Two
bullous diseases were recognized at that time, pemphigus and its
variants, and dermatitis herpetiformis and its variants. Curiously
‘‘The affections comprehended by the term pemphigus were
formally greater in number because several disease entities have
been identified and otherwise clarified in recent years.’’ Porphyria
cutanea tarda was a likely example of this recognized change in
classification. In 1953, Walter Lever published his recognition and
description of bullous pemphigoid (BP) as being distinct from
bullous pemphigus. He did this by noting that this bullous disease
had unique histologic features and a characteristic infiltrate of
inflammatory cells that accompanied the separation of the
epidermis from the dermis at the BMZ [124]. By 1964, he had
sufficiently utilized his appreciation of the features of this disease in
the laboratory and in the clinic to permit publication of a
monograph dedicated largely to differences between pemphigus
and pemphigoid [125]. In 1967, the group led by Jordon and
Beutner discovered the presence of immunoreactants in the BMZ of
skin of patients with pemphigoid along with circulating antibodies
to the BMZ of normal human skin [126]. This discovery was fueled
by this group’s previous success in finding immunoreactants in
pemphigus at the location of the histo-pathologically recognized
site of this disease, intercellular acantholysis of the epidermis
[127,128]. These studies confirmed Lever’s convictions and
launched a new era for the study of bullous diseases of the skin.
The technologies (listed in Table III) that led to this era have been
instrumental to the generation of the current classification and
understanding of the pathogenesis of bullous diseases of the skin
with immunoreactants at the BMZ (see Table IV).
Cormane, in 1967, recognized immunoglobulin deposits in the
dermis of patients with dermatitis herpetiformis (DH) [129]. In 1969,
van der Meer and co-workers found that these deposits were IgA
[130]. Two years later, Chorzelski and co-workers extended this
observation and noted that 10%–15% of DH patients did not have
the usual granular deposits in their papillary dermis (see Fig 13);
rather, they had a linear deposition of IgA at the BMZ [131] (see Fig
13). Technologies such as immunomicroscopy, immunogenetics
and small bowel biopsy cause us to now recognize that patients
with linear IgA deposits have a disease which is similar to but
distinct from DH; hence, the distinction linear IgA disease (LAD)
(see below).
For some time, epidermolysis bullosa acquisita (EBA) has also
been recognized as having immunoreactants at the BMZ, usually
IgG [132–135]. In 1984, Woodley, Gammon, Briggaman, and
colleagues isolated and identified an antigen from the BMZ to
which patients with EBA react. This antigen localizes to the area of
the BMZ where the IgG, usually found in skin affected with this
disease, localizes, the sub-lamina densa [136–138]. This caused
these investigators to propose that EBA had an immunopathologic
basis distinct from other bullous diseases [136]. Thus, another
bullous disease moved from the category of an uncharacterized
bullous disease to a distinct entity.
In 1938, herpes gestationis was felt to be a variant of dermatitis
herpetiformis associated with pregnancy. However, recognition by
Provost and Tomasi in 1973 [139] of a complement component, C3,
at the BMZ in lesional skin was quickly confirmed by other groups
and led to the recognition of this disease as a distinct entity
[140,141]. The subsequent description of HG factor as an IgG
directed at a yet undefined antigen of the BMZ, which avidly fixes
Table III. Techniques Utilized to Characterize and
Establish a Pathogenic Role for Immunoreactants
Associated with Bullous Disorders of the BMZ
A. Discovering the Immunoreactants
1. Light microscopy
2. Electron microscopy
B. Characterizing the Immunoreactants
1. Purification of antibodies
a) Separation techniques
b) Monoclonal antibodies
2. Purification of antigens
a) Extraction and separation techniques
b) Generation of antigen via DNA hybridoma technology
3. Approaching genetic control of production of immunoreactants
a) Correlation with class I and II MHC loci of chromosome 6
b) Identification of the aberrant gene
C. Establishing a pathogenic role for immunoreactants
1. Comparing involved to uninvolved
2. Correlating with disease activity
3. In vitro models
a) Role of antigen-specific components
b) Role of amplification of the inflammatory process
i) inflammatory cascades and their inhibitors
ii) the inflammatory infiltrate
iii) other inflammatory cascades and their inhibitors
iv) molecular basis of disease
Table IV. Bullous Diseases with Immunoreactants at
the Basement Membrane Zone
A. Immunoreactants are primarily IgG
1. Bullous pemphigoid
2. Cicatricial pemphigoid
3. Herpes gestationis
4. Epidermolysis bullosa acquisita
5. Bullous lupus erythematosus
B. Immunoreactants are primarily IgA
1. Dermatitis herpetiformis
2. Linear IgA disease
3. Bullous disease of childhood
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and binds C3, solidified the notion that this was a distinctive disease
[142,143].
In 1971, scarring of mucous membranes of what is now called
cicatricial pemphigoid was recognized as a clinical entity distinct
from pemphigus and pemphigoid [144]. However, as Rogers et al,
in 1977, noted in their large series, the pattern of immunoreactants
in cicatricial pemphigoid was not different from that of BP [145].
Not until 1984 did localization of immunoreactants throughout the
BMZ in cicatricial pemphigoid distinguish it as being an entity
distinct from BP. In BP, the immunoreactants remain in the upper
BMZ [146]. This supported the notion that these diseases differed
and were likely mediated via recognition of different antigens.
Chronic bullous disease of childhood has been defined as a
childhood form of DH and BP. Immunohistologic techniques allow
these diseases to be separated from chronic bullous disease of
childhood. However, investigations have not advanced sufficiently
to permit this disease to be separated from LAD [147–149]. It seems
likely that the antigen(s) of the BMZ of LAD will be characterized in
the near future (see below). This characterization will enable
investigators to determine whether chronic bullous disease of
childhood and LAD are truly separate diseases.
Accumulation of a number of immunoreactants at the BMZ in
lupus erythematosus appears to have been first identified in 1963
and 1964. This was possible because of the availability of
immunohistologic techniques, which were described earlier (see
below) [150,151]. Considerable detail on the nature of these
immunoreactants is available but lies outside the limitation of this
overview. However, bullae do uncommonly develop in systemic
lupus erythematosus. Curiously, these patients, while having the
necessary criteria to carry the diagnosis of LE, most frequently (76%)
have granular IgA deposited at the BMZ in perilesional and
nonlesional skin and carry antibodies that react with the EBA
antigens of the BMZ [152,153].
Perspective on Technology
Overview Technology has been, and will continue to be, key to
moving from a reproducible insightful finding to a complete
understanding of the biology or pathology of skin. Three stages
can be identified in this process: discovering, characterizing, and
establishing the pathogenesis (Table III). In immune/inflammatory-
mediated skin disease, finding an abnormality has been followed by
characterization (e.g., where is the aberration in immunoreactants
located relative to disease expression? and What is the relationship
with the course of the disease?) Pemphigus was the first bullous
disease in which immunoreactants were found [127]. Subsequent
research has shown that the putative antibody of pemphigus vulgaris
fluctuates in a fashion that correlates with the clinical expression of
disease [154,155]. Such linkage suggests that the immunoreactants
in pemphigus are not an epiphenomenon. While failure of linkage
supports the notion that the finding is an epiphenomenon, it is also
possible that it merely reflects an insufficient understanding of the
basic biologic processes which, curiously, are usually secondary to
limitations in technology.
Proving that immunoreactants in skin are causative of the
biologic and pathologic process requires experimentally fixing and
then manipulating the variables. This has become increasingly
complex with our appreciation of the complexity of skin as an organ
with its repertoire of cells, matrices, and interactive message
systems. This complex interactive organ acts orchestrally in such a
manner as to give rise to a functioning organ that is, in itself,
variable, e.g., palms and soles vs. axilla vs. scalp, etc. Nevertheless,
technology, coupled with insightful investigators, has generated
systems that utilize skin as an organ in vivo or in vitro, as a whole or
in part, and the requisite investigations have been accomplished.
Pemphigus is illustrative. Acantholysis of the epidermis of skin in
organ culture, of epidermal cells in culture, and of the epidermis of
newborn mice can be induced with the simple incubation or
injection of patient serum containing high antibody titers to the
putative pemphigus antigen [156–160]. Given the foregoing
complexity of skin and an ever-growing complexion of interactive
immune/inflammatory mediator systems, the final proof of cause
and effect has been a major challenge. With a consistent reaction
pattern, there comes the general belief that the biologic and
pathologic events giving rise to this pattern can be explained at the
molecular level. Current wisdom dictates that every molecular
species of a cell and its interaction with that cell or another cell is
controlled at the level of the gene. A statement of this concept is
simple; implementation is not. Pemphigus clearly has a genetic
predisposition, but is usually not acquired until long after birth
[161]. The fluctuating course of the disease and the putative
antibody causing pemphigus vulgaris suggests that events occur
which lead to a faulty antigen recognition process or faulty
regulation of an as yet poorly defined inhibitory process, or both.
A complete understanding of the molecular basis of this is not likely
until the genes that permit the unusual antibody recognition and/or
faulty regulation are understood in the context of other gene
products which have a role in disease expression. The desire to have
this type of understanding serves as the underpinning for the major
scientific challenge before the scientific community, sequencing the
entire human chromosome, 3 billion nucleosides.
Application of Advances in Immunology to Bullous Diseases of
Skin In 1942, Coons and co-workers described the principles of
modern immunofluorescence and, in 1950, the location of antigen
in tissue using this technology [162,163], While the technology had
been available, it was not until 1963 when Burnham and co-
workers described immunoglobulins at the BMZ in skin involved
with lupus erythematosus (Fig 14). This paper, the ninth most
frequently quoted article in the JID [151], is seen as the beginning of
the modern era of studying immunoreactants in skin. This
observation was rapidly followed by already noted findings of
circulating and fixed immunoreactants in many bullous diseases.
The precise localization of immunoreactants in the skin has proven
extremely valuable in directing research and classifying disease.
This subcellular localization was facilitated by techniques that
Figure 13. Direct immunofluorescence staining with monospecific anti-IgA
conjugate in a biopsy of skin from a patient with dermatitis herpetiformis.
Specific granular fluorescence was seen in the dermis ‘‘at the dermal
epidermal junction’’ (Chorzelski et al: J Invest Dermatol 56:373–380, 1971).
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permitted the use of the electron microscope in localizing
immunoreactants, immunoelectron microscopy. Wolff and Schrei-
ner first used the immuno-peroxidase technique to localize the
intracellular deposition of immunoglobulin unique to pemphigus
[164]. In two highly cited papers published in 1975, ranked 13th
and 124th in the most frequently cited articles in the JID, Holubar
et al and Schaumburg-Lever et al localized the immunoglobulins of
BP to the lamina lucida [165,166] (Fig 15). This technology was key
to permitting investigators to believe that EBA was likely a separate
bullous disease, even though light microscopy revealed immuno-
reactants at the same location in the skin as seen in
pemphigoid [138].
Purification of antibodies via separation technology led to the
isolation of specific antibodies, i.e., antibodies that can recognize
unique epitopes on the antibody molecule itself as well as
antibodies that are very specific for an antigen. This led to the
molecular make-up of antibody (heavy and light chains, etc.)
subclasses of antibody, joining and secretory pieces, etc. Without
these specific reagents, the advances in understanding and
characterizing diseases, e.g., DH, could not have been accom-
plished. The ultimate methodology for purifying antibodies has been
that used to generate monoclonal antibodies. Paller and co-workers
applied this technology to a bullous disease. They isolated the EBA
antigen and generated a monoclonal antibody to it [167]. This
reagent, because of its specificity, has been utilized (as noted above)
to determine if other bullous diseases have circulating immunor-
eactants to the same antigen. As has been recently shown, the
antigen specific for EBA and bullous systemic lupus erythematosus
appears to be the same, Type VII collagen [152,153]. Again,
technology, in this case a monoclonal antibody specific for Type VII
collagen, was key to this new knowledge [168].
Techniques for purification of antigen are numerous. Technology
that is being increasingly exploited is that which generates purified
antigens by processes which isolate the gene, generate the specific
antigen, and facilitate the generation of antigen in large quantities in
biologic form via DNA hybridization techniques.
The response to antigens, foreign or self, is, as noted, genetically
regulated. The technology surrounding immunogenetics has led
investigators to recognize that some autoimmune diseases, including
bullous diseases of the skin, are in linkage disequilibrium with various
phenotypes of the class I and II antigens of the major histocompat-
ibility locus of chromosome 6 (see below). The linkage of these genes
to the abnormal response in these patients will be greatly facilitated
by the proposed experimental sequencing of the human genome.
Proving that the immunoreactants present at the BMZ cause the
clinical pathology has been difficult, not only because of the
complex make-up of skin, its nutrients, and mediators, but also
because of our proper concern for indiscriminate testing on human
subjects. Models to establish a pathogenic role for a disease (BP)
with circulating immunoreactants to the BMZ have been recently
described in the JID and the Journal of Clinical Investigation
[169–171], and have shown that immunoreactants seen in situ are
likely to be pathogenic in vivo (see below). Linkage of the findings
in in vivo and in vitro systems with the type of correlations noted in
Table III (section C) provides compelling, if not direct, evidence of
cause and effect.
Coordinate with the advancement of insight into the role of
immunoreactants in the skin has been the recognition and definition
of mediators of inflammatory cascades, e.g., complement [172].
Initially, there was only an appreciation of these pathways.
However, because of molecular definition there has been a flurry
of activity that deals with the amplification system of the immune
system via cytokines released not only by cells of the immune
system but by cells constituent to skin [57–58,62,173–175]. The
current technology for purification and production of biologic
mediators along with increasingly sophisticated in vivo and in vitro
systems currently available to study skin bode for the likelihood of
continued progress.
HIGHLIGHTS OF TECHNOLOGICAL ADVANCES:
IMMUNOREACTANTS AT THE BMZ
This section highlights the contributions of technology over the past
50 years to the current understanding of the bullous diseases listed
in Table IV. Four of these diseases (see Table V, A–D) have been
selected as best typifying this objective. Current reviews have been
helpful [136,161,172,176–180], as well as two slightly older but
highly quoted JID papers (ranked fourth and 44th on the most cited
list) on pemphigoid and pemphigus [181] and on dermatitis
herpetiformis [182].
Bullous Pemphigoid Bullous pemphigoid (Table IIIA) occurs most
commonly on the flexural surfaces of the limbs and in about one-
third of the cases on mucous membranes [125]. Curiously, the
antigen(s) of BP, which is expressed extracellularly in the lamina
lucida and intracellularly in epithelial cells in association with
hemidesmosomes, does not appear to be equally expressed over the
entire body [183,184]. One of the antigens of BP has been
described as a 220-kD protein [185]. Other antigens appear likely,
suggesting that the BP patient has a unique proclivity to recognize
antigens of the BMZ or that BP represents a heterogeneous group of
diseases that share very similar clinical characteristics [186,187].
The immunoreactants present in involved skin include the third
component of complement (C3), IgG (usually IgG4 subclass), and less
frequently IgA andlgM [126,161,188–190]. Recently, the terminal
attack complex of complement has been found in lesions and in
decreased intensity in perilesional skin (Fig 16). This difference
suggests a pathogenic role for this complex [191]. Additionally, two
patterns of inflammatory cell infiltrate are seen in BP: inflammatory
cell poor (usually seen on the extremities), and inflammatory cell rich
(more likely to occur elsewhere) with eosinophils predominating as
the inflammatory cell infiltrate [161,183].
In uninvolved sites (perilesional), IgG (usually IgG4 subclass) is
present in the lamina lucida in 90% of subjects, with C3 being
present in near 100% of all cases [126,188–190]. Approximately
70% of patients have circulating IgG which binds to the BMZ. This
Figure 14. Figure 2 from a paper by Burnham et al Q Invest Dermatol
41:451–456,1963). This is a frozen section from a lesion of lupus
erythematosus that has been incubated with fluorescein-labeled goat anti-
human gamma globulin. This photograph illustrated a well-demarcated band
of bright yellowish-green fluorescence at the dermal-epidermal junction.
Patchy yellow-green fluorescence is present in the dermis ( 250).
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incidence can be increased to 90% with enhancing techniques
[126,188,192,193]. Unexplained is the reason for the titer of BP
antibody(s) not correlating with disease activity [154,188].
In contrast to DH and EBA, BP is not linked to the currently
defined parameters of the immunogenetic locus of chromosome 6
(see below) [194].
The effector mechanism of the putative mediators of BP has yet
to be elucidated. There is abundant literature to suggest that
complement, classical, and alternative pathways, as well as their
inhibitors, are important [70,139,196–202]. Partially purified IgG to
the BP antigen(s) has been injected into rat cornea and guinea pig
skin and has caused histologic lesions similar to BP [170,171]. The
observation that neutrophils will bind to frozen sections of
perilesional skin of patients with BP in the presence of a fresh
source of complement prompted Gammon et al to exploit this as a
model system to study the role of inflammatory cells in the
pathogenesis of bullous diseases [201]. They have shown that BP
serum, complement, and neutrophils in combination, but not
individually, will lead to vesiculation when incubated in concert
on frozen sections of human skin [169].
It is hypothesized that autoantibodies are generated to one or
more proteins that are normally made by keratinocytes and
transported to the lamina lucida in patients with BP. The trigger,
e.g., increased antigen deposition, increased antibody production or
decreased inhibitors of the initiation of the inflammatory cascade
which results in a lesion, is unknown. However, inflammatory cells,
especially eosinophils, mast cells, and/or neutrophils, are felt to be
substantial contributors [172,176].
Some intriguing associations occur with this disease that will
likely be clarified once the disease is understood on a molecular
basis. These include the following: 1) the fact that the disease
usually has its onset late in life and spontaneously waxes and wanes
[125,202]; 2) the fact that there is no uniform precipitating factor,
but that there is an association with other autoimmune diseases
(recently reviewed by Korman) [176]; 3) the observation that the
disease responds not only to anti-inflammatories (corticosteroids),
but also to immunosuppressives (cyclophosphamide and azathio-
prine) and to agents that have less dramatic effects on the
inflammatory/immune system (tetracycline in combination with
niacinamide) [203].
Epidermolysis Bullosa Acquisita (EBA) Since EBA (Table IVB) has
been recognized as a distinct clinical entity that is acquired, it has
been noted that the lesions can develop in response to trauma (the
noninflammatory variety), and can develop with overt signs of
inflammation but without trauma. Unlike BP, EBA usually occurs on
acral and extensor surfaces, but like BP it can occur on mucous
Figure 15. Figure 7 from a paper by Holubar et al (J Invest Dermatol 64:220–227,1975). This demonstrates, ultrastructurally, the location of immunoglobulins in
bullous pemphigoid skin using a new peroxidase-antiperoxidase multi-step method. Lesional skin from periphery of a bulla with detachment of the keratinocytes
(KC) from the dermis. The basal lamina (BL) rests on the dermis. A: Control (omission of the first step in the immunochemical chain). There is no reaction product
(22,200). B: Specimen run through the entire immunochemical chain. Electron-dense precipitate (arrows) is localized on the cytomembrane of the detached
keratinocytes. Small amounts of the granular reaction pattern are present in the basal lamina (BL) resting on the dermis ( 22,000). Inset: High-power view of the
reaction product (arrows) on the membrane of a keratinocyte which shows detachment from the underlying basal lamina (BL) and subadjacent dermis
(83,600).
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membranes [136]. The antigen of EBA is a matrix protein of the
lamina densa and sub-lamma densa and is present in all
mammalian skin [137,138,204] (Fig 17). The EBA antigen is a
macromolecule with a 290- and 145-kD species. The higher
molecular weight moiety is collagenase sensitive, and the other is
not [136]; as noted, the EBA antigen has been described as Type VII
collagen [168].
The immunoreactants in involved and uninvolved (perilesional)
skin of patients with EBA are IgG in 100%, with IgM, IgA, and C3
being present in some [136]. Most patients (70%) with EBA have a
circulating IgG which binds to both the 290- and the 145-kD
moieties on Western blot analysis [136,204].
Patients with the bullous form of systemic lupus erythematosus
have anti-BMZ antibodies that also recognize the EBA antigen
[152,153]. There is now some evidence that EBA is in linkage
disequilibrium with a MHC class II allele (HLA-DR2). Patients with
bullous lupus erythematosus may also have a similar association
[205]. The antibody to EBA antigen from patients with EBA is more
active in the human skin (antibody, complement, neutrophil) model
described by Gammon, i.e., increased binding of neutrophils and
vesiculation occur at higher dilutions [206]. To complete the
understanding of the effector mechanism of immunoreactants in
EBA, it will be necessary to understand how a bulla can form
secondary to trauma in a noninflammatory background and how at
Table VA. Technology-Driven Advances in Bullous
Pemphigoid
A. Anatomic Location of Immunoreactants/Nature of Antigen
1. Location
a) Upper lamina lucida of the BMZ
b) Intracellularly with hemidesmosomes
c) Not expressed equally on body surface
2. Nature of antigen
220–240 kD protein; may be heterogeneous
B. Immunoreactants
1. Involved skin, IgG (IgG4 and C3)
a) Most lesions are inflammatory cell rich (eosinophils)
b) Some lesions are inflammatory cell poor
c) Membrane attack complex of complement is present
2. Uninvolved skin (perilesional)
a) IgG (IgG4) in most
b) Linear C3 is common; IgA and IgM is less common
c) Membrane attack complex of complement present but decreased
3. Circulating immunoreactants
a) 70–90% have IgG to BMZ
b) BP antigen antibody titers do not correlate with disease activity
C. Immunogenetics—no known association
D. Effector mechanism—BP antibody, complement, and inflammatory
cells
E. Associated phenomena
1. Onset late in life with no uniform precipitating factor, spontaneous
waxing and waning
2. Associated autoimmune disorders are common
Table VB. Technology-Driven Advances in
Epidermolysis Bullosa Acquisita
A. Anatomic Location of Immunoreactants/Nature of Antigen
1. Location
Lamina densa and sub-lamina densa, present in all mammalian skin
2. Nature of antigen
Type VII collagen, 290 kD/145 kD species
B. Immunoreactants
1. Involved sites—linear IgG in all
2. Uninvolved sites—same as involved sites
3. Circulating immunoreactants, IgG to 290/145 kD antigen of the BMZ
in 70% of subjects
C. Immunogenetics—possible linkage to HLA-DR2
D. Effector mechanism—increased antigen, increased antibody, or
decreased inhibitory factors lead to inflammatory/selected proteolytic
process.
E. Associated phenomena
1. Relative resistance to glucocorticoids and immunosuppressive drugs
2. Has inflammatory and noninflammatory phase—immunoreactants
present in both
Table VC. Technology-Driven Advances in Dermatitis
Herpetiformis
A. Anatomic Location of Immunoreactants
Sub-basal lamina/papillary dermis/microfibrils
B. Immunoreactants
1. Involved sites, IgA (IgA,) and neutrophils are present
2. Uninvolved sites, IgA, complement (alternative pathway and
membrane attack complex) are present
3. Circulating immunoreactants
a) IgA immune complexes in some
b) Anti-gluten antibodies
c) Anti-reticular antibodies
C. Immunogenetics
HLA-B8/DR3/DQw2, class I and class II phenotype in nearly all patients
D. Effector mechanism
IgA in skin (specific vs. nonspecific) triggers inflammatory cascade and
influx of PMNs, proteolysis, and vesicle
E. Associated phenomena
1. Dramatic response to dapsone/sulfapyridine
2. Gluten sensitive enteropathy
—villous atrophy of small bowel
—fluctuation of disease and immunoreactants in skin with gluten
ingestion and withdrawal
3. Worse with halogens
4. Increased frequency of autoimmune phenomena
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other times it can develop spontaneously in a background of
inflammation, and why the presence of immunoreactants, e.g., the
nonlesional skin, does not result in lesions [136].
Very curious in the category of associated phenomena is the
observation that EBA is quite resistant to corticosteroids and
immuno-suppressants. In this regard, it stands in contrast to the
other diseases under discussion [136,176].
Dermatitis Herpetiformis (DH) This disease (Table VC) has under-
gone considerable definition in the past 50 years. It has progressed
from a well-recognized disease with characteristic pruritic vesicles
over extensor surfaces, to a more defined entity, with granular
deposits of IgA in the papillary dermis on immunomicroscopy.
Further, during these 50 years it has been learned that DH responds
favorably to dapsone and sulfapyridine, and that it has well-
recognized genetic and intestinal aberrations as well as a sensitivity
to gluten ingestion, the latter being somehow important to disease
expression in most patients (see below).
Anatomically, the immunoreactants of DH are located in the sub-
basal lamina of the papillary dermis in association with microfibrils
[207–210] (Fig 18). The immunoreactants in involved sites are few
(possibly secondary to the inflammatory process associated with the
lesion) and are primarily IgA [131,182]. In contrast, perilesional skin
‘‘always’’ has the well-recognized granular deposition of IgA (usually
Table VD. Technology-Driven Advances in Linear IgA
Disease
A. Anatomic Location of Immunoreactants
1. Lamina lucida in most
2. Sub-lamina lucida in some
B. Immunoreactants
1. Involved sites—not studied
2. Umnvolved sites
—IgA ‘‘always present;’’ usually IgA,
—complement not studied
—circulating immunoreactants present in 450%
C. Immunogenetics
HLA-B8/DR3 phenotype normal to elevated
D. Effector mechanisms—same as dermatitis herpetiformis
E. Associated phenomena
1. Dramatic response to dapsone/sulfapyridine
2. No villous atrophy of the small bowel
Figure 16. Figure 3 from a paper by Dahl et al (J Invest Dermatol 82:132–135,
1984). This demonstrates the membrane attack complex of complement at the
BMZ of perilesional skin of bullous pemphigoid. The deposits of membrane
attack complex form a linear array (arrow). The fluorescent material in the
dermis is elastic tissue which is autofluorescent (160).
Figure 17. Figures 3 (A) and 4 (B) from a paper by Briggaman et al (J Invest
Dermatol 85(suppl):79s–84s, 1985). These differentiate epidermolysis bullosa
acquisita from pemphigoid utilizing immunoelectron micrographic
techniques. A: Direct immunoelectron micrograph of the perilesional skin
of a patient with the inflammatory phase of EBA (Case 2). Immune
deposit (D) is seen in and beneath the lamina densa (14,600). B: Indirect
immunoelectron micrograph with circulating IgG anti-BMZ antibody from
patient with EBA showing immune deposit (D) in and beneath the lamina
densa ( 14,600).
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IgAt subclass without secretory piece or J-chain), frequently in
association with complement components [129,130,131,
179,211–216]. There is evidence of activation of the alternate
complement pathway and of the membrane attack complex being
present in perilesional skin of patients with DH [211,217,218]. Zone
et al have recently reported that the immunoreactants increase
perilesionally as one approaches a lesion, and are unlikely to be
present in skin that has never had a lesion [219,220]. The
immunoreactants diminish with cessation of gluten ingestion but in
a delayed fashion [178,221–222]. Some patients with DH have IgA
immune complexes circulating in their blood that may fluctuate with
gluten ingestion [213,223–226]. Patients have antireticulin
antibodies and more appear to have circulating anti-gluten and
gluten-associated antibodies [180,227–230].
Nearly all patients with DH have an association with the MHC
phenotype [HLA-B8/DR3/DQw2(Te24)], and there is some evi-
dence of genetic transmission [231–237]. This phenotype (at least
the B8/DR3 locus) is associated with other autoimmune phenomena
[180,238].
Because IgA is deposited where pathology occurs (papillary tips of
the dermis), and because IgA deposition fluctuates with gluten
ingestion as does the disease, it is felt that the IgA deposits are
somehow causative of the disease [178,180]. The neutrophil appears
to be the primary inflammatory cell in the vesicular lesion
[178,180,182]. A major question remains: In DH, as well as other
bullous diseases with immunoreactants in uninvolved skin, ‘‘How do
the immunoglobulin deposits (in this case IgA) trigger the inflamma-
tory cascade?’’ A prevailing hypothesis is that unknown triggers
(increased antigen, increased antibody, decreased inhibitors) invoke
the complement cascade pathway with subsequent development of a
lesion [178–180]. Extraction of IgA from skin and defining the
antigen(s) to which the IgA binds will be pivotal to further definition
of this component of the pathogenesis of DH [239–240].
A major associated phenomenon with DH was the discovery of
the linkage to gluten-sensitive enteropathy [241–244]. With this
came gluten withdrawal as therapy and the immuno genetics
linkage noted above. The response to dapsone and sulfapyridine is
dramatic for the skin component of DH and other bullous diseases
where IgA deposits are prominent. However, the bowel abnormality
associated with these diseases is not affected by these drugs
[178,180,182]. Another unexplained curiosity is the worsening of
DH with halogen ingestion [182,245]. Innovative investigators,
cooperative patients, and the application of research skills currently
available, and to be developed, again are seen as key to further
breakthroughs.
Linear IgA Disease (LAD)With the recognition of IgA deposits in the
skin of patients with DH came the recognition that some (about
10%–15%) had IgA deposited linearly along the BMZ [179,182,246]
(Table VD). This led some to consider it as a variant of pemphigoid
with IgA as a primary immunoreactant, and others to see it as a
variant of DH because of its clinical presentation and response to
treatment [182,210,247]. The failure to consistently find the
gastrointestinal abnormality characteristic of DH (villous atrophy),
the more near normal incidence of HLA-B8/DR3 phenotype
[180,248], and the finding that patients with LAD have circulating
anti-BMZ antibodies (see below) have caused investigators to feel
that DH and LAD are separate entities [178,180]. Support for this is
the preliminary evidence that epidermal cells make the bullous
pemphigoid antigen but not a LAD antigen, currently identified as a
97-kD protein [249,250].
Two localizations of immunoreactants have been noted in LAD,
most commonly in the lamina lucida and less commonly below the
lamina lucida [180,210,247,250]. The separation of bullous SLE
and sub-lamina densa LAD awaits results of further purification of
antigen of these diseases, testing for cross-reacting antibodies, and
ultimately clinical correlation studies to further define the clinical
and laboratory aspects of these diseases [152].
The immunoreactants in LAD in involved sites have not been
investigated. IgA (usually IgA, without J-chain) is always present in
uninvolved (perilesional) sites, as this is how the disease is currently
defined [216,246]. The role of complement (the alternative pathway
and membrane attack complex, etc.) has not been reported. Patients
with LAD have anti-BMZ antibodies (IgA) in their serum; antibodies
being present in 4/11 patients using 1.0M NaCl split skin in one
preliminary study, and in 9/10 in another preliminary study
[180,250].
The effector mechanism for LAD has not been elucidated but is
felt to be similar to the pathway causing DH because the histology
and response to treatment are similar [178–180]. Some patients with
LAD have an inflammatory infiltrate in their bowel but not the
villous atrophy associated with DH [180,248]. This suggests that
gluten withdrawal will not be beneficial to patients with LAD;
however, this is yet to be studied.
CONCLUSIONS
This perspective illustrates that research into clinical entities by
investigative technology has proven to have considerable clinical
relevance. Although one could argue that having nine bullous
Figure 18. Figure 4 from a paper by Stingl et al (J Invest Dermatol 67:507–512,1976). This localizes the immunoreactants in dermatitis herpetiformis using HRP-
anti-HRP sandwich technique. Electron-dense reaction product associated with the microfibrillar component of an elastic fiber. Note accentuation of the
periodicity of the microfibrils by finely granular precipitates. Amorphous elastin (E) and collagen fibers (C) are devoid of HRP deposits ( 22,200).
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diseases in 1988 vs two in 1938 is a step backward, i.e., life is now
more complicated, reflection will cause the opposite conclusion to
be reached. With better defined diagnoses, clinicians can discuss
the natural history of the disease with their patients with greater
accuracy and insight. These insights will also allow the clinician to
more accurately predict and assess the response to treatment. It
must be recognized that this is possible only because of research of
the immune and inflammatory responses in skin. Without such
research efforts, the discovery of immunoreactants in skin would not
have occurred, and therapies that are immunomodulatory would
probably never have been considered for many cutaneous diseases.
Research has allowed us to consider drugs such as azathioprine,
cytoxan, and cyclosporine as rational therapies for the management
of inflammatory disorders of the skin. Patterns of immunoreactants
have become indicators for particular drug therapies: IgA deposits
suggest dapsone or sulfapyridine, while IgG deposits suggest
corticosteroids, cyclophosphamide, and other immunosuppressive
therapies.
From our perspective, the past 50 years have been truly exciting.
The capability of investigators and technology make it likely that the
next 50 years will be even more productive and exciting. The SID
through its organ, the JID, is especially proud to have been
responsible for disseminating much of this critical information.
G. G. Krueger would like to express special gratitude to John J. Zone for his notion of presenting
these advances from a technological viewpoint and for his hours of discussion. G. Stingl thanks
Mrs. Sylvia Hermanek and Mrs. Renate Koppfor carefully typing the manuscript, and his wife
Laura for many helpful suggestions.
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